Webinar: Overcoming Biomarker Data Chaos with a Single Data Platform
Duration: 30 minutes
Register for the Webinar:
Translational and clinical research teams spend more than 70% of their time wrangling information from disconnected clinical trial data sets.
Data ends up in silos, making it hard to compile information and surface insights.
Watch this short webinar, where Adam Brown and Mike Waters will demonstrate how integrating exploratory biomarker, PK, and clinical data in a unified data platform enables teams to interrogate trends and identify insights as data is generated on-study.
4 Strategic Imperatives for Clinical and Biomarker Operations
Keeping track of clinical trial samples across multiple sites and vendors can be manual and tedious (recent post) -- we have demonstrated how virtual Sample Inventory Management can streamline the day-to-day reporting of sample collections, shipments, and discrepancies (webinar series).
Read More →
Webinar: Monitoring Site and Vendor Performance Metrics Across Studies
Duration: 30 minutes
Register to Watch On Demand:
Summary
Clinical and translational teams must monitor biomarker samples across global site footprints and dispersed networks of labs and biorepositories.
It's easy to get bogged down by managing the day-to-day requirements of keeping studies on track. With samples as the critical first step toward data generation, modern trials demand a unified approach for evaluating vendor and site performance and their impact on sample operations.
Join our webinar to learn how our team has been working with sponsor Read More →
Streamlining vendor oversight: Monitoring site-level and laboratory performance across multiple oncology trials
The challenge: Maintaining clinical trial timelines dependent on vendor performance
A global biotechnology company with seven clinical-phase programs approached QuartzBio with a challenge shared by many organizations in the industry -- overall assessment of clinical trial vendors and sites was time-consuming and unreliable, given global site footprints, complex sample lifecycles, and inconsistent naming across sites and vendors.
Tasked with preparing regular executive summaries, the company’s clinical and biomarker operations teams were spending significant time deriving trial-wide key performance indicators (KPIs), lacking visibility into vendor performance – and challenged to translate current experience into future study Read More →
